NCT01931670View on ClinicalTrials.gov

A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

815

Participants

Timeline

Start Date

September 9, 2013

Primary Completion Date

January 6, 2016

Study Completion Date

December 19, 2016

Conditions
Endometriosis
Interventions
OTHER

placebo

DRUG

Elagolix

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY